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Abstract: Late-life depression (LLD) is both a prevalent and life-threatening disorder, affect-
ing up to 13.3% of the elderly population. LLD can be difficult to identify because patients 
mainly consult their general practitioner (GP) for somatic complaints. Moreover, patients may 
be hesitant to express the problem to their GP. Increased vigilance on the part of the GP can 
only benefit older people with depression. To recognize the risk of LLD, screening tools are 
provided in addition to treatment options for LLD. This review aims to provide the GP with 
guidance in recognizing and treating LLD. It tries to connect mainstream etiologies of LLD 
(e.g., vascular, inflammation, hypothalamo–pituitary–adrenal axis) with risk factors and cur-
rent therapies. Therefore, we provide a basis to the GP for decision-making when choosing an 
appropriate therapy for LLD.
Keywords: geriatric mental health, major depressive disorder, elder care, psychosomatic, 
geriatric psychiatry
Introduction
Late-life depression (LLD), with an estimated prevalence of 13.3%, is a common 
mental health disorder in older people.1 It is associated with increased morbidity and 
mortality in addition to a high societal cost.2 Moreover, the treatment cost of an older 
person with depression is 1.86 times higher than that of an older person without depres-
sion.3 The consequences of untreated LLD include poor quality of life, exacerbation of 
chronic illnesses, and suicide.4 Due to the atypical presentation, the diagnosis is often 
missed by general practitioners (GPs), which consequently leads to undertreatment of 
the disease.5 However, an LLD diagnosis in time can be life-saving and, when treated, 
LLD has a good prognosis; up to 70% of older patients with depression treated with 
antidepressants recover from a depressive episode.6 The aim of this review is to provide 
a comprehensive and practical guide for GPs with regard to the main risk factors as 
well as the diagnostic and therapeutic approach to LLD.
Definition of the problem
LLD can be defined as depression that occurs for the first time after age 60. When 
we use the term “depression”, we refer to major depressive disorder as defined by 
the Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5). The cardinal 
symptoms of major depressive disorder are anhedonia (a loss of interest in activities 
one used to enjoy) and a depressed mood through most of the day.7 According to the 
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DSM 5, an older person has an episode of major depression 
if he or she has at least one cardinal symptom and four or 
more of the following symptoms for at least 2 weeks: sig-
nificant decrease or increase in weight or appetite; insomnia 
or hypersomnia, fatigue, psychomotor agitation, or retarda-
tion; diminished ability to concentrate or make decisions; 
feelings of worthlessness or inappropriate guilt; and recur-
rent thoughts of death or suicidal ideation. In the elderly, 
depressive feelings may often be masked by unexplained 
physical complaints (e.g., fatigue, diffuse pain or back pain, 
headache, chest pain, etc.) and, consequently, the classical 
DSM 5 criteria sometimes seem to fail in terms of diagnosing 
depression in elders.8
Furthermore, the conditions mentioned above can exist 
concomitantly. The differential diagnosis of LLD is broad 
(Table 1). Physical examination and cognitive screening may 
be useful in ruling out common conditions that are often 
confused with depression and in assessing for commonly 
co-occurring diseases. Consequently, a thorough medical 
history, Mini Mental State Exam, physical examination, 
and, sometimes, further technical investigations are recom-
mended. Indications for referring patients to a geriatric 
psychiatrist are presented in Table 2.8
A particularly difficult differential diagnosis of LLD is 
dementia (see Table 3). Moreover, Parkinson disease (PD) is 
a prevalent neurodegenerative disease associated with depres-
sion and occurs in up to 35% of patients with PD.10 Depres-
sion associated with PD is not a single entity, but rather a 
heterogeneous group of three subtypes where only one group 
is directly related to the pathophysiology of PD.11 The signs 
of depression linked to PD include nonresponse to at least 
one course of antidepressant treatment, absence of suicidal 
behavior, absence of guilt and self-blame, and no personal 
history of depression. The pathophysiological mechanism 
of depression in PD is unknown, but a current hypothesis 
Table 1 Differential diagnosis of late-life depression
Central nervous system disorders (dementia, Parkinson disease, and 
neoplastic lesions)
Related psychiatric disorders (dysthymia, bipolar, and anxiety disorders)
endocrine disorders (hypothyroidism, hyperthyroidism, and 
hyperparathyroidism)
Adverse events of some pharmacological agents (e.g., β-blockers, 
centrally active antihypertensive medications, steroids, H2-blockers, 
sedatives, certain chemotherapy agents)
Life circumstances (e.g., grief, bereavement, financial loss)
Substance use, abuse, or dependence
Infectious and inflammatory diseases (e.g., HIV encephalopathy, systemic 
lupus erythematosus) and sleep disorders (in particular, obstructive 
sleep apnea)
Note: Data from Fountoulakis et al.9
Table 2 Summarizing table
Patients at risk for late-life depression
•	 Poor physical health and frailty
•	 Female gender
•	 Oldest elders (≥80 years)
•	 Cognitive impairment and 
neurodegenerative disease
•	 Nutritional deficits
•	 vascular events
•	 Lifestyle: smoking, alcohol, 
multiple medications
•	 Being single or widow(er)
Screening tools 
GDS CES-D PHQ2
•	 Yes/no format
•	 Takes 3–4 min to 
complete
•	 validated for the oldest 
elders and MMSe >10
•	 Preferred screening tool 
for Parkinson disease 
•	 Cutoff 30-item list: 10–19, 
mildly depressed 20–30, 
severely depressed
•	 Cutoff 15-item list: ≥5, 
major depressive disorder
•	 Scoring statements 
with 0–3 scores
•	 Takes 5 min to 
complete
•	 validated in 
patients suffering 
from dementia
•	 Cutoff: ≥20, major 
depression 
•	 Two yes/no 
questions
•	 Takes <1 min to 
complete
•	 If positive, 
further 
investigations 
are necessary
Treatment options based on stepped care
Nonpharmacological Pharmacological ECT
•	 Psycho-education
•	 Psychotherapy
•	 Patients who prefer 
talking over medication
•	 As adjunctive therapy
•	 Structured physical 
exercise 
•	 Frequency: 3–4 times a 
week
•	 One session: 
45–60 min
•	 Substitution 
therapy (when 
deficit is present)
•	 vitamin D: 
2,000 IU daily
•	 Folic acid: 
800 µg–2 mg
•	 Antidepressants
•	 SSRIs (e.g., 
sertraline)
•	 TCAs (e.g., 
nortriptyline) 
•	 SNRIs (e.g., 
duloxetine, 
venlafaxine)
•	 Mirtazapine
Reserved for 
•	 Oldest elders 
(≥80 years)
•	 Treatment-
refractory 
depression
•	 Psychotic 
depression 
•	 Depression 
with severe 
weight loss and 
anorexia
•	 Psychomotor 
agitation or 
retardation 
Consider referral to a mental health specialist: preference 
nonpharmacological treatment, persistent depression (one to three 
trials of antidepressants), psychosis, mania, or concern about suicide
Abbreviations: GDS, Geriatric Depression Scale; CeD-D, Center for epidemiologic 
Studies; PHQ2, Patient Health Questionnaire; MMSe, Mini–Mental State examination; 
ECT, electroconvulsive therapy; SSRIs, selective serotonin reuptake inhibitors; TCAs, 
tricyclic antidepressants; SNRIs, serotonin–norepinephrine reuptake inhibitors.
implies genetic factors, Lewy body pathology, stress-induced 
hypercortisolemia, inflammation, psychosocial aspects, and 
changes in monoaminergic signaling.10
In the assessment of LLD, exclusion of somatic causes 
of depression through patient history, clinical examination, 
laboratory tests, and/or imaging is the first step in appraising 
LLD.12 A GP who has good knowledge of the patient’s per-
sonality can identify nonverbal cues and changes in behavior 
suspicious for mood problems.13 In addition, information 
from family members and/or caregivers on the patient’s mood, 
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functioning and behavior is crucial for assessing the older 
person with depression.
There is no golden standard for bringing up depression; 
it is dependent on the physician’s manner, and research on 
the topic is lacking. To engage the patient, the use of the 
bio-psychosocial model may be helpful: inform the patient 
that the illness is an interaction between physiological (e.g. 
serotonin hypothesis), psychological, and social factors.14
Risk factors
The risk factors for LLD are a combination of biological and 
psychosocial factors.
Biological risk factors
The biological risk factors associated with LLD are old age 
and female sex.15 In addition, there may be a genetic vulner-
ability, making some people more susceptible to LLD than 
others.16
Patients with poor physical health (e.g. multiple comor-
bidities, sleeping disorders, etc.) may be predisposed to 
LLD.17 These people often use more medication, which in 
itself is a risk factor for LLD.18
The concept of frailty stresses a loss of function in several 
domains of functioning (not only the physical), leading to 
a decline in the reserve capacity for dealing with stressors. 
Frailty can be defined by the Fried criteria: weight loss, 
decreased handgrip strength, slowness, exhaustion, and 
low physical activity.19 Physical frailty is linked to chronic 
inflammation and LLD.20,21 Poor nutritional status is associ-
ated with frailty; therefore, nutritional supplements (vitamin 
D and proteins) could benefit the depressed frail patient.22 
Nutritional deficits that are often reported in older people 
with depression are vitamin B12 and folate deficiencies.23 
The current hypothesis states that vitamin D affects mood 
by interacting with brain receptors in the limbic structures 
and hippocampus.24
Neurodegenerative disease (e.g., PD or Alzheimer) and 
mild cognitive impairment (MCI) has also been considered a 
possible risk factor for LDD.25 There are hypotheses that LLD 
may lead to MCI and, consequently, dementia.25 The debate is 
still ongoing, and the current literature is inconclusive about 
LLD being a prodrome of dementia.27 What we do know is 
that LLD and dementia frequently co-occur, and depression 
can be the first sign of dementia.28,29
The vascular hypothesis states that cerebrovascular 
disease may cause or predispose to LLD. The concept of 
vascular depression as a clinical entity is inherently linked 
to this hypothesis and can be explained by reduced cerebral 
perfusion, altered brain connectivity due to vascular brain 
lesions, and chronic low-grade inflammation.30 LLD has been 
linked to atherosclerosis, which is – at the same time – the 
leading cause of coronary heart disease.31
Psychosocial risk factors
Kaji et al point out that psychological factors such as loss of 
purpose in life or human relationships seem to be associated 
with LLD.32 Moreover, lower education has been linked to 
LLD.33 Being a widower or single is a risk factor for LLD, 
but possibly reflects the fact that loneliness, lack of social 
support, and stressful life events or poverty are the risk fac-
tors for depression in old age.34 Being functional or visually 
impaired increases the risk of developing LLD.35
Poor lifestyle habits can put elders at risk for LLD. Both 
smoking and alcohol use are the risk factors of LLD.18 In 
Table 3 Differential diagnosis: late-life depression versus dementia
Late-life depression Dementia
Onset Slow or acute Slow and progressive onset
evolution Chronological order of events can be recalled History of the disease cannot be restored by the patient
Quality of life (as experienced by 
the patient)
Decreased The patient does not experience his/her disease as a 
problem
Memory Decreased ability to think or concentrate or being 
slowed down
Decreased
Impaired ability to learn new information or to recall 
previously learned information
Patient tries to hide cognitive problems
Language and praxis Normal Decreased
Affect Apathetic, depressed mood, psychomotor retardation Lability of affect 
Somatic Sleep disturbances
Somatic problems (insomnia, dizziness, pain, etc.)
Low energy
Diurnal mood variation
Can be present, but will not be chief complaint
Prognosis Treatable Irreversible
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addition, the use of sleep medication has been linked to LLD, 
but sleep disturbance in general is a risk factor for LLD.35
Screening
In the following text, we only discuss screening tools 
validated in a geriatric and primary care setting. These tools 
should not be used systematically; rather, an opportunistic 
screening is advised in patients in whom LLD is suspected. In 
Table 4, we compare the Geriatric Depression Scale (GDS), 
Center for Epidemiologic Studies Depression Scale (CES-D), 
and Patient Health Questionnaire 2 (PHQ-2).
Approach
The recommended approach to LLD is stepped care: treat-
ment is based on the severity of depression and preference of 
the.42 The severity of the depressive disorder (mild, moderate, 
or severe) is based on the number of symptom criteria, the 
severity of those symptoms, and their functional disability in 
the DSM-5. If the selected treatment for LLD is inadequate, 
the GP should step up and provide the next step of treatment 
(see Figure 1). A summary of risk factors, screening tools, 
and interventions are provided in Table 2.
Prevention
The risk factors that can be modified are nutritional deficien-
cies and cardiovascular disease, which are more common at 
older ages.43,44
Vascular risk factors can be improved by exercise, diet, 
smoking cessation as well as treatment for hypertension, 
hypercholesterolemia, and hyperglycemia.45,46 These inter-
Table 4 Comparison of validated screening tools for late-life depression in primary care
Geriatric Depression Scale (GDS)-1536 Center for Epidemiologic Studies 
Depression Scale (CES-D)37
Patient Health 
Questionnaire 2 (PHQ-2)38
what Yes/no questionnaire A short self-report scale of 20 statements, divided 
into multiple categories, designed to measure 
depressive symptoms over the past week
Questions depressed mood 
and anhedonia in the previous 
2 weeks
Cutoff 5 25 Positive response to one of the 
two questions
Sensitivity 79%–100%37 85%39 100%4
Specificity 67%–80%37 64%39 77%4
Time to complete 3–4 min 5 min 1 min
extra 1. validated in the oldest elder (≥80 years) 
with cognitive impairment (lower limit: 
Mini-Mental Status exam 10)40
2. Preferred screening instrument in 
Parkinson patients
Can be used for patients with patients with 
dementia (average Mini-Mental Status exam score 
of 19)41
Suicide risk
or not
responsive
Severe
Moderate
Mild
• Hospital admission
• Psycho-education, active monitoring, and behavioral activation
• Psychotherapy
• Psychotherapy
• Combined treatment with antidepressant and psychotherapy
• Combined treatment with antidepressant and psychotherapy
• Collaborative care
• Referral to mental health practitioner
• Antidepressants
Figure 1 Stepped care approach to late-life depression, based on the severity of depression and patient preference. Initiate the next step if the patient does not respond 
to the therapy.
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ventions reduce the further progression of atherosclerosis 
and prevent diabetes and cerebrovascular disorders – all of 
which are linked to LLD.45,47
Nutritional supplementation, such as a high dose of vita-
min D (2,000 IU daily), folic acid (800 µg–2 mg), and a high-
protein diet (for frail elders), for a deficiency of vitamins or 
folic acid in older people (including the frail) with depression 
has been suggested to alleviate depressive symptoms.22,24,48
Nonpharmacological treatment
Psycho-education
The GP plays a central role in providing psycho-education: 
to clarify major depressive disorder, to explain therapeutic 
options, discuss biopsychological vulnerability, to teach 
to recognize warning signs, and to inform and support the 
spouse.49 In addition, the primary physician actively monitors 
the patient through frequent visits. Moreover, the primary 
physician tries to provide a structure in the patient’s life and 
activate the patient through structured and fun activities.50 
The structure provided must be manageable for the patient 
and should lead to positive feelings. A balance between tasks 
and relaxation is essential. Healthy food, sufficient sleep, and 
daily interactions are a prerequisite.
Behavioral activation
Structured physical activity is recommended for older 
people with mild or moderate depression who are physically 
capable and can be motivated to exercise.51 Exercise is safe 
and effective in addition to the pharmacological treatment of 
depression.51 Mere referral of an older person with depression 
is not enough.52 Primary care physicians and psychiatrists 
should take an active role in keeping the patient motivated 
and managing the exercise-related adverse effects.53 A recent 
meta-analysis recommends structured, supervised exercise 
programs, three times a week (45–60 min), over 10–14 weeks, 
and at low intensity for mild to moderate depression.51
Psychotherapy
Psychotherapy is the most important type of nonphar-
macological treatment. In LLD, psychotherapy decreases 
depressive symptoms in older people with depression.54 
Psychotherapeutic interventions can prevent LLD in older 
people with sub-syndromal depression55 and are not inferior 
to pharmacological treatment.56 Evidence-based psycho-
therapeutic treatments of depression in older adults include 
cognitive behavioral therapy (CBT), problem-solving therapy 
(PST), reminiscence therapy, and interpersonal therapy 
(IPT).57 One relatively new therapy is life review therapy, 
where the patient shares and talks about important life events 
and memories with their therapist. A randomized controlled 
trial (RCT) proved that life review therapy is effective in 
depressed older adults and also reduces anxiety.58 In addi-
tion, life review therapy has already been implemented with 
success in a structured multidisciplinary approach in nursing 
homes and led to reduced prevalence of depression.50
Pharmacological treatment
Older adults have different pharmacodynamics and phar-
macokinetics due to age-related physiological changes.59 
Medication must be administered at lower doses or slowly 
titrated while actively monitoring the patient.60 Patients 
with comorbidities usually take multiple drugs. Increased 
vigilance for drugs interactions is, therefore, necessary.61 A 
careful review of the patient’s drug history is recommended. 
Moreover, when choosing a psychotropic drug, one needs 
to keep track of the drug’s safety profile. Because falls can 
invalidate old adults and even lead to increased mortality 
(hip fracture), avoid medications that sedate the patient.62,63
In primary care, both tricyclic antidepressants (TCAs) 
and selective serotonin reuptake inhibitors (SSRIs) are the 
pharmacological treatments of choice.64 Existing evidence 
suggests that no one class of antidepressant drugs has been 
found to be more effective than another in the treatment of 
LLD.65 Although newer antidepressants are not more effec-
tive than older ones, they are better tolerated and are safer, 
especially in cases of overdose.60 The adverse effect data 
suggest the modest superiority of SSRIs over TCAs.66 When 
choosing an SSRI, slight preference goes to an SSRI with 
the least known drug interactions such as sertraline or (es)
citalopram. Citalopram has a Food and Drug Administration 
(FDA) black-box warning for increased risk of arrhythmia 
(QTc prolongation), which is why sertraline is preferred over 
citalopram.67 TCAs are as effective as SSRIs for LLD, but are 
less often used because of frequent side effects.68 TCAs with 
lesser anticholinergic side effects, such as nortriptyline, are 
recommended by the authors. Both SSRIs and TCAs are asso-
ciated with fracture risk, although causality is not proven.69
Serotonin and noradrenaline reuptake inhibitors (SNRIs; 
e.g., duloxetine, venlafaxine) are an alternative to SSRIs 
for depressed older adults when SSRIs are ineffective or 
contraindicated.70,71 SNRIs are not only effective against the 
major depressive disorder but also effective in the treatment 
of peripheral neuropathic pain.
Another second-generation antidepressant that can be 
used as an alternative for SSRIs is mirtazapine. The seda-
tive side effects of mirtazapine are used as a treatment for 
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insomnia.72 In addition, mirtazapine improves the appetite 
and can be used for anorexia.73 The effect of mirtazapine on 
sodium levels is limited, and therefore, less hyponatremia is 
noted in patients taking mirtazapine.74
Important and frequent side effects and contraindications 
of antidepressants are reported in Table 5.
electroconvulsive therapy
An effective treatment for LLD, available from mental health 
specialists, is electroconvulsive therapy (ECT). In ECT, an 
electrical stimulus is given for a brief period to produce a 
generalized seizure. Multiple RCTs have proved that ECT 
is beneficial for LLD, especially psychotic depression, 
treatment-refractory depression, catatonia, and depression 
with severe weight loss and anorexia.75,77 ECT is an effec-
tive and safe treatment for depression in adults, including 
the oldest elders (≥80 years).77 Recent evidence suggests 
old age is a positive predictor of response to ECT: it gives 
faster and higher remission rates as compared to antidepres-
sants.78 A meta-analysis of the cognitive effects of ECT 
suggests its relative safety and the transient character of its 
effects on memory.79 Autobiographical memory is affected 
by ECT, but restored or improved 6 months after treatment.80 
Compared to antidepressants, ECT induces a higher speed 
of remission.81
Multidisciplinary approach
A multidisciplinary approach to LLD can be achieved 
through a collaborative care model. Collaborative care was 
designed in the United States for patients with (chronic) 
depression, wherein the GP who cares for a depressed elder 
is supported by a care manager and a multidisciplinary team 
comprising a psychiatrist and nurses. In this model, there is a 
shared responsibility of the depressed patient and the patient 
can benefit from different albeit synergistic approaches of 
LLD. Collaborative care is more effective than the standard 
care by GPs and was successfully tested in the United States, 
England, and the Netherlands.82–85 In general practice, the 
patient and his close family members can be invited once 
or twice a year to a “home meeting”. Those present at these 
meetings are the most relevant caregivers: the physiotherapist, 
the social worker, the home nurse, the occupational therapist, 
and the GP. In this meeting, the patient can express his\her 
needs, whereas the other members can balance what’s going 
well with what can improve the treatment of the patient. 
These recommendations then guide the treatment plan. If 
deemed necessary, the patient can be extensively investigated 
in a geriatric day-care hospital. In a few cases of severe and 
recurrent depression, a case manager (e.g., working in a 
geriatric psychiatric clinic) can be asked to coordinate the 
implementation of the defined treatment plan.
Conclusion
LLD is a prevalent disease that often presents with atypical 
symptoms and more somatic (co)morbidities and complaints. 
A stepped care model to treat depression is advised, taking 
into account the severity of the depression. Due to the somatic 
co(morbidities), a collaborative care model is preferred. 
The collaborative care model has proven efficacy and cost-
effectiveness in LLD.
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